Site is Being Upgraded

Managing glaucoma with branched chain amino acids: Branched chain amino acids increase Nmnat1 expression, increase NAD+ levels, improve neuronal dysfunction, and protect against glaucoma via down regulation of its target gene, 31/March/2018,  9.29 pm

A candy way to treat blood sugar disease: Sugar-based therapy for autoimmune diabetes (TIDM): Raffinose, a trisaccharide composed of galactose, glucose and fructose, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 31/March/2018, 12.15 am
March 30, 2018
A sweet way to treat pain: Trisaccharide-based activation of the PD-1 pathway for Pain therapy: Raffinose, a trisaccharide composed of galactose, glucose, and fructose, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 31/March/2018, 10.57 pm
March 31, 2018
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Managing glaucoma with branched chain amino acids: Branched chain amino acids increase Nmnat1 expression, increase NAD+ levels, improve neuronal dysfunction, and protect against glaucoma via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

Figure 1. Mechanistic insights into how branched chain amino acids(BCAA) glaucoma. BCAA, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

Figure 2. BCAA functions as an anti-glaucoma agent by increasing NAD+ levels

This study suggests, for the first time, that Branched chain amino acids(BCAA), by increasing the expression of their target gene, they may increase the expression of Nmnat1. Thereby, they may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; (4) increase insulin sensitivity; and (5) alleviate glaucoma (Fig.1). Thus, branched chain amino acids,  either alone or in combination with other drugs, may be used to treat Glaucoma.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How branched chain amino acids increase the levels of NAD+

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Managing glaucoma with branched chain amino acids: Branched chain amino acids increase Nmnat1 expression, increase NAD+ levels, improve neuronal dysfunction, and protect against glaucoma via down regulation of its target gene, 31/March/2018,  9.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.